Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”

The authors regret that this protocol must now be amended to increase the number of patients included from 48 to 57.

In the abstract for “This phase II study (ClinicalTrials.gov NCT03202758) will assess the efficacy and safety of FOLFOX/D/T association in patients with mCRC (n=48).” read “This phase II study (ClinicalTrials.gov NCT03202758) will assess the efficacy and safety of FOLFOX/D/T association in patients with mCRC (n=57)”.

Under Statistical consideration, for “48 patients are needed” read “57 patients are needed”.

The authors would like to apologise for any inconvenience caused.